22 April 2026
22 April 2026
GlobalData analysts forecast a blockbuster future for Idvynso, though they note it is unlikely it will displace market dominator, Biktarvy.
Prenosis will use its precision medicine platform to analyse biospecimens and data from BioAegis’ Phase II BTI-203 trial.
Denosumab therapies are used to increase bone mass and treat osteoporosis, as well as address bone complications in cancer.
Lilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which analyst Jack Cuthbertson says will give the company a broader chance for success.
The new site will focus on the use of AI models for purposes including the discovery and development of targeted medicines for patients with unmet medical needs.
Aicuris’ overall revenue is anticipated to reach $500m by 2030, not including AIC468.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
